Operating Expenses (Annual)

Operating Expenses: The sum of all operating expenses for the given industry.

Pharma Mar (PHMMF) had Operating Expenses of $181.79M for the most recently reported fiscal year, ending 2025-12-31.

Quarterly Annual

Figures for fiscal year ending 2025-12-31

Income Statement Financials
Revenue	$250.48M
Net Income	$84.84M
Cost of Goods Sold	$13.87M
Gross Profit	$236.61M
Operating Expenses	$181.79M
Operating Income	$68.69M
Non-Operating Income/Expense	$-1.20M
Pre-Tax Income	$67.49M
Normalized Pre-Tax Income	$67.49M
Income after Taxes	$84.84M
Income from Continuous Operations	$84.84M
Consolidated Net Income/Loss	$84.84M
Normalized Income after Taxes	$84.84M
EBIT	$68.69M
EBITDA	$77.77M
Weighted-Average Shares Outstanding (Basic)	17.43M
Weighted-Average Shares Outstanding (Diluted)	17.45M
Earnings per Share (EPS) (Basic)	$4.87
Earnings per Share (EPS) (Diluted)	$4.87
Balance Sheet Financials
Current Assets	$320.66M
Property, Plant, and Equipment	$64.93M
Long-Term Assets	$126.34M
Total Assets	$446.99M
Current Liabilities	$106.21M
Long-Term Debt	$40.22M
Long-Term Liabilities	$55.86M
Total Liabilities	$162.07M
Common Equity	$284.92M
Tangible Shareholders Equity	$280.91M
Shareholders Equity	$284.92M
Common Shares Outstanding	17.36M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$60.11M
Cash Flow from Investing Activities	$-68.78M
Cash Flow from Financial Activities	$-41.32M
Beginning Cash	$71.55M
End Cash	$20.16M
Increase/Decrease in Cash	$-51.39M
Stock-Based Compensation	$2.32M
Common Stock Dividends Paid	$-15.78M
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	3.02
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.12
Debt to Equity Ratio	0.18
Gross Margin	94.46%
Operating Margin	27.42%
EBIT Margin	27.42%
EBITDA Margin	31.05%
Pre-Tax Profit Margin	26.94%
Profit Margin	33.87%
Free Cash Flow	$52.80M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.56
Inventory Turnover	0.23
Receiveable Turnover	5.62
Days Sales in Receivables	64.97
Return on Equity	29.78%
Return on Tangible Equity	30.20%
Return on Assets	18.98%
Return on Investments	26.09%
Book Value Per Share	$16.41
Free Cash Flow per Share	$3.03
Operating Cash Flow per Share	$3.44

Data from Zacks Investment Research, Inc.